The scientific value of multicentre trials could be considered from two different points of view. Many and well defined exclusion and inclusion criteria will produce a homogenous trial population and thereby reliable data. But too many exclusion criteria will give results only valid for a subset of patients and not suitable for generalisation in clinical practice. Comparison of results in randomised and non randomised patients will often show better results in randomised patients. This is frequently claimed to be caused by better medical care for randomised patients, but it may also be caused by selection of patients with better prognosis for randomised studies. Information about all patients fulfilling randomisation criteria, included as well as excluded, should therefore be available when the results from multicentre trials are evaluated.
In 1981, 55 departments of gynaecology and surgery, 11 institutes of pathology and four centres of oncology established the Danish Ovarian Cancer group, DACOVA. These departments cover about 2/3 of the population in Denmark. Since 1981 the group has performed several controlled randomised trials comparing different treatment modalities. The group has tried to register all patients in its catchment area. This makes it possible to compare treatment and results for randomised and non randomised patients and analyse escape clauses in the trials.
From September 1981 to November 1984 the DACOVA group performed two randomised studies for epithelial ovarian cancer: one for adjuvant treatment of FIGO stages Ib, Ic or II (Sell et al., 1990) , and one for chemotherapy treatment of FIGO stages III and IV (Bertelsen et al., 1987) .
The aim of the following paper is to compare treatment and survival in randomised and non randomised patients and to analyse the reasons for excluding patients fulfilling protocol criteria.
Materials and methods
From September 1981 to November 1984, 716 patients with epithelial ovarian cancer were registered in the DACOVA register. The registration procedure was as follows: a recordform should be filled in every time a new case of ovarian cancer was diagnosed. An attempt was made to register all patients with malignant epithelial ovarian cancer. The record form was sent directly to the DACOVA register in patients not fulfilling inclusion criteria for the randomised studies. In patients fulfilling inclusion critera the record form was sent to the regional oncologic centre, when the patient was referred for postoperative treatment. After randomisation performed locally, the record form was sent to the DACOVA register. Only cases with histologic verification of diagnosis were registered. Patients diagnosed at laparoscopy or postmortem examination were also included. (Scully, 1977) and histological grading according to the percentage of solid tissue (Mauch et al., 1980) : well-differentiated less than 10% (grade I); moderately differentiated more than 10% and less than 50% (grade II); poorly differentiated more than 50% (grade III). All randomised patients had a routine pathological review by an experienced gynaecologic pathologist. FIGO (Dembo et al., 1979) . Both randomised studies showed no survival differences between the regimens (Sell et al., 1990; Bertelsen et al., 1987) .
Non randomised patients in early stages were mainly treated with a combination of pelvic irradiation and cyclophosphamide, or with cisplatinum containing chemotherapy, if they had postoperative therapy at all. Advanced stages were treated with different chemotherapy regimens.
Follow-up Follow-up information was collected prospectively for all randomised patients. For non randomised patients information about primary surgery and pathology was collected prospectively, and information about treatment, recurrence, and survival was obtained retrospectively. Cut-off day was July 1990. Observation time is 68-106 months. No patient was lost to follow-up.
Statistical method
Survival was estimated by the Kaplan Meier method and tested for differences by the Mantel Haenzel test. Survival was calculated from the date of operation to the date of death or 1 July 1990 -whichever occurred first.
Exclusion reasons
The reasons for exclusions were divided in unavoidable and avoidable reasons. Exclusion criteria foreseen in the protocol, postoperative death, diagnosis at autopsy, psychiatric disease, and doubt about the histologic diagnosis at start of postoperative treatment were considered as unavoidable exclusion reasons. Exclusion of patients because of medical condition not allowing chemo-radiotherapy is of course a subjective decision. But the majority of patients excluded by medical contraindication had very advanced disease.
DATA calculation
It was estimated that patient accrual for the adjuvant protocol would be 50 patients per year and for the chemotherapy protocol 100 patients per year. The number required for a statistically significant difference of 15% was calculated to 300 patients in both trials. (Table II) . Three hundred and thirty-seven or 70% of the 481 eligible patients were included in the randomised trials. The total number of eligible patients and the number of randomised patients varied a little from year to year. The first year 68% was randomised, the second 74%, and the third 70%.
In early stages 120 patients fulfilled inclusion criteria (Table II) Survival for all patients showed that randomised patients had a better survival than non randomised patients (Figure 1 ).
The difference was statistically significant (P = 0.0005). For stages Tb, Ic or II there were no difference between survival in randomised and non randomised patients (P = 0.45) but stages III and IV randomised patients had a statistically significant better survival than non randomised patients (P = 0.0002). The survival superiority in randomised patients disappeared when groups with similar stages and treatments were compared. In stages III and IV there was no difference in survival when only patients treated with combination chemotherapy were compared ( Figure 2) The percentage of randomised patients in the present study was similar to the percentage of eligible patients randomised in other Danish multicentre trials. The Danish colo-rectal multicentre study group included 57% of eligible patients in a randomised study testing the efficacy of postoperative irradiation in colo-rectal cancer Dukes stage B and C (Kronborg et al., 1988) . The majority (92%), was excluded because of reasons agreed upon beforehand. However, this trial had a very long list of protocol exclusion criteria. In the Danish Breast Cancer Cooperative Group 20-30% of patients below 70 years of age were not included in the various protocols (West Andersen et al., 1988) .
Survival of randomised patients was better than survival of non randomised patients. This is probably caused by selection of patients with better prognosis for randomised studies. Non randomised patients were patients with bad prognosis. The difference in survival disappeared when groups with similar prognostic characteristics and similar treatments were compared. Thus, advanced stages treated with cisplatinum containing chemotherapy showed no survival difference between randomised and non randomised patients.
For early stages the number of randomised patients was below the estimated number, 20 vs 50 per year. For advanced stages the estimate was correct. Both trials were unable to show a statistically significant survival difference between the randomisatioiL groups. The protocol for early stages stopped in November 1988. A study testing the effect of adjuvant treatment in early ovarian cancer will require participation of a large number or departments because of the small number of patients in stages I and II. The chemotherapy protocol stopped in November 1984 after inclusion of 265 patients. Recently this trial has been analysed together with four other trials randomising between CAP and CP (Ovarian Cancer Meta-Analysis Group, 1991). The five trials included 1,194 patients. A statistically significant difference for 5 year survival in favour of the CAP regimen was observed (P = 0.02). The observed difference was 6% and not 15% as estimated. Considering the poor survival of advanced ovarian cancer the 6% improvement is of clinical interest. A realistic estimate of the expected difference at the beginning of the trial would have demonstrated that a large scale study with participation of departments outside Denmark was necessary. A large scale trial had required a different study design recording only very few data.
The present study showed that the patient allocation to a multicentre trial is influenced by many factors. In setting up randomised trials the following should be considered.
(1) Only essential and simple questions should be examined in multicentre trials. (2) Realistic data estimates should be performed. Patient accrual and the difference between treatments groups are usually overestimated. A statistically significant difference will very often require inclusion of a large number of patients. (3) Participation of departments randomising a small and selected part of their patients is questionable. Results based on data from these selected patients may be of no use in clinical pratice.
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